Coherus BioSciences (CHRS) Announces Repurchase of Approximately $170M of Convertible Notes
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Stocks fall as higher oil prices, Treasury yields weigh
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
- Bloom Energy shares fall on Oracle project halt
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
- Oppenheimer sees AI software winners as focus shifts to ROI
- Arm Holdings falls as CFO stock sale weighs on sentiment
- Cantor Fitzgerald Starts Lexicon Pharmaceuticals (LXRX) at Overweight
Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes
April 1, 2025 8:00 AM EDTRemaining $60 Million of outstanding convertible notes to be repurchased post-close of pending UDENYCA divestiture
REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus or the Company, NASDAQ: CHRS) announced today that it has entered into privately negotiated transactions (the Repurchases) with certain holders (the Holders) of its 1.500% Convertible Senior Subordinated Notes due 2026 (the Convertible Notes), pursuant to which the Company agreed to repurchase approximately $170 million aggregate principal amount of the Convertible Notes from such holders at a cash repurchase price equal to 100% of their principal amount,... More
